Auditory and visual P300 reflecting cognitive improvement in patients with schizophrenia with quetiapine: A pilot study

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 34, Issue 4, 2010, Pages 674-680

  Park, E Jin ^a   Han, Sang Ick ^a   Jeon, Yang Whan ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

Cognitive function; P300; Quetiapine; Schizophrenia; Symptom

Indexed keywords

ALPRAZOLAM; AMISULPRIDE; ARIPIPRAZOLE; DIAZEPAM; HALOPERIDOL; LORAZEPAM; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ADULT; ARTICLE; AUDITORY DISCRIMINATION; AUDITORY STIMULATION; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DOSE ESCALATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ELECTROENCEPHALOGRAPHY; EVENT RELATED POTENTIAL; EVOKED AUDITORY RESPONSE; EVOKED VISUAL RESPONSE; FEMALE; HUMAN; LATENT PERIOD; MALE; OUTCOME ASSESSMENT; PILOT STUDY; POSITIVE AND NEGATIVE SYNDROME SCALE; SCHIZOPHRENIA; TASK PERFORMANCE; TREATMENT DURATION; TREATMENT OUTCOME; VISUAL DISCRIMINATION; VISUAL STIMULATION;

ACOUSTIC STIMULATION; ADULT; ANALYSIS OF VARIANCE; ANTIPSYCHOTIC AGENTS; BRAIN MAPPING; CEREBRAL CORTEX; COGNITION; DIBENZOTHIAZEPINES; ELECTROENCEPHALOGRAPHY; EVENT-RELATED POTENTIALS, P300; EVOKED POTENTIALS, AUDITORY; EVOKED POTENTIALS, VISUAL; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PHOTIC STIMULATION; PILOT PROJECTS; QUESTIONNAIRES; SCHIZOPHRENIA; SEVERITY OF ILLNESS INDEX; SIGNAL PROCESSING, COMPUTER-ASSISTED; TREATMENT OUTCOME;

EID: 77952673810     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2010.03.011     Document Type: Article

References (68)

1. Addington J., Addington D. Premorbid functioning, cognitive functioning, symptoms and outcome in schizophrenia. J Psychiatry Neurosci 1993, 18:18-23.
2. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 1994, American Psychiatric Press, Washington, DC. 4th ed.
3. Andreason N.C., O'Leary D.S., Flaum M., et al. Hypofrontality in schizophrenia; distributed dysfunctional circuits in neuroleptic-naïve patients. Lancet 1997, 349:1730-1734.
4. Bellack A.S., Gold J.M., Buchanan R.W. Cognitive rehabilitation for schizophrenia: problems, prospects, and strategies. Schizophr Bull 1999, 25:257-274.
5. Chung Y.C., Li Z., Dai J., et al. Clozapine increases both acetylcholine and dopamine release in rat ventral hippocampus: role of 5-HT1A receptor agonism. Brain Res 2004, 1023:54-63.
6. Coburn K.L., Shillcutt S.D., Tucker K.A., et al. P300 delay and attenuation in schizophrenia: reversal by neuroleptic medication. Biol Psychiatry 1998, 44:466-474.
7. Demiralp T., Uçok A., Devrim M., et al. N2 and P3 components of event related potential in first-episode schizophrenic patients: scalp topography, medication, and latency effects. Psychiatry Res 2002, 111:167-179.
8. Duncan C.C., Donchin E. The P300 component of the event-related brain potential as an index of information processing. Biol Psychology 1982, 14:1-52.
9. Egan M.F., Duncan C.C., Suddath R.L., et al. Event-related potential abnormalities correlate with structural brain alterations and clinical features in patients with chronic schizophrenia. Schizophr Res 1994, 11:259-271.
10. Eikmeier G., Lodemann E., Zerbin D., et al. P300, clinical symptoms, and neuropsychological parameters in acute and remitted schizophrenia: a preliminary report. Biol Psychiatry 1992, 31:1065-1069.
11. Farde L., Ito H., Swahn C.G., et al. Quantitative analyses of carbonyl-carbon-11-WAY-100635 binding to central 5-hydroxytryptamine-1A receptors in man. J Nucl Med 1998, 39:1965-1971.
12. Ford J.M., White P.M., Lim K., et al. Schizophrenics have fewer and smaller P300s: a single-trial analysis. Biol Psychiatry 1994, 35:96-103.
13. Ford J.M., White P.M., Csernansky J.G., et al. ERPs in schizophrenia: effects of antipsychotic medication. Biol Psychiatry 1994, 6:153-170.
14. Gallinat J., Riedel M., Juckel G., et al. P300 and symptom improvement in schizophrenia. Psychopharmacology 2001, 158:55-65.
15. Gold J.M. Cognitive deficits as treatment targets in schizophrenia. Shcizophr Res 2004, 72:21-28.
16. Gonul A.S., Suer C., Coburn K., et al. Effects of olanzapine on auditory P300 in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2003, 27:173-177.
17. Green M.F., Nuertherlein K.H. The MATRICS initiative: developing a consensus cognitive battery for clinical trials. Schizophr Res 2004, 72:1-3.
18. Halgren E., Baudena P., Clarke J.M., et al. Intracerebral potentials to rare target and distractor auditory and visual stimuli: I. Superior temporal plane and parietal lobe. Electroencephalogr Clin Neurophysiol 1995, 94:191-220.
19. Halgren E., Baudena P., Clarke J., et al. Intracerebral potentials to rare target and distractor auditory and visual stimuli. II. Medial, lateral, and posterior temporal lobe. Electroencephalogr Clin Neurophysiol 1995, 94:229-250.
20. Hegerl U., Juckel G., Muller-Schubert A., et al. Schizophrenics with small P300: a subgroup with a neurodevelopmental disturbance and a high risk for tardive dyskinesia?. Acta Psychiatr Scand 1995, 91:120-125.
21. Higashima M., Urata K., Kawasaki Y., et al. Event-related potential abnormalities and clinical syndromes in schizophrenics. Advances in event-related brain potential research 1996, 979-983. Elsevier, Amsterdam. C. Ogra, Y. Koga, M. Shimokochi (Eds.).
22. Huang M., Li Z., Ichikawa J., et al. Effects of divalproex and atypical antipsychotic drugs on dopamine and acetylcholine efflux in rat hippocampus and prefrontal cortex. Brain Res 2006, 1099:44-55.
23. Iwanami A., Okajama J., Isono H., et al. Effects of risperidone on event-related potentials in schizophrenic patients. Pharmacopsychiatry 2001, 34:73-79.
24. Jeon Y.W., Polich J. Meta-analysis of P300 and schizophrenia: patients, paradigms, and practical implications. Psychophysiology 2003, 40:684-701.
25. Juckel G., Muller-Schubert A., Gaebel W., et al. Residual symptoms and P300 in schizophrenic outpatients. Psychiatry Res 1996, 65:23-32.
26. Kay S.R., Fiszbein A., Opler L.A. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987, 13:261-276.
27. Knight R.T. Distributed cortical network for visual attention. J Cogn Neurosci 1997, 9:75-91.
28. Korostenskaja M., Kahkonen S. What do ERPs and ERFs reveal about the effect of antipsychotic treatment on cognition in schizophrenia?. Curr Pharm Des 2009, 15:2573-2593.
29. Korostenskaja M., Dapsys K., Siurkute A., et al. Effects of olanzapine on auditory P300 and mismatch negativity (MMN) in schizophrenia spectrum disorders. Prog Neuropsychopharmacol Biol Psychiatry 2005, 29:543-548.
30. Korostenskaja M., Dapsys K., Siurkute A., et al. The effect of quetiapine on auditory P300 response in patients with schizoaffective disorder: preliminary study. Ann Clin Psychiatry 2009, 21:49-50.
31. Kuroki T., Meltzer H.Y., Ichikawa J. Effects of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens. J Pharmacol Exp Ther 1999, 288:774-781.
32. Kutas M., McCarthy G., Donchin E. Augmenting mental chronometry: the P300 as a measure of stimulus evaluation time. Science 1977, 197:792-795.
33. Laurent A., Garcia-Larrea L., Dalery J., et al. The P300 potential in schizophrenia. Encephale 1993, 19:221-227.
34. Lili C.K., Kimberley P.G., Heather M., et al. Treatment of a first episode of psychotic illness with quetiapine: an analysis of 2year outcomes. Schizophr Res 2006, 81:29-39.
35. Maeda H., Morita K., Kawamura N., et al. Amplitude and area of the auditory P300 recorded with eyes open reflect remission of schizophrenia. Biol Psychiatry 1996, 39:743-746.
36. Mathalon D.H., Ford J.M., Pfefferbaum A. Trait and state aspects of P300 amplitude reduction in schizophrenia: a retrospective longitudinal study. Biol Psychiatry 2000, 47:434-449.
37. Maurer K., Dierks T., Laux G., et al. Topographic mapping of EEG and auditory evoked P300 in neuropsychopharmacology. Pharmacopsychiatry 1988, 21:338-342.
38. McCarthy G., Luby M., Gore J., et al. Infrequent events transiently activate human prefrontal and parietal cortex as measured by functional MRI. J Neurophysiol 1997, 77:1630-1634.
39. Meltzer H.Y., McGurk S.R. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr Bull 1999, 25:233-255.
40. Meltzer H.Y., Park S., Kessler R. Cognition, schizophrenia, and the atypical antipsychotic drugs. Proc Natl Acad Sci 1999, 96:13591-13593.
41. Molina V., Munoz F., Martin-Loeches M., et al. Long-term olanzapine treatment and P300 parameters in schizophrenia. Neuropsychobiology 2004, 50:182-188.
42. Mueser K.T., Douglas M.S., Bellark A.S., et al. Assessment of enduring deficit and negative symptom subtypes in schizophrenia. Schizophr Bull 1991, 17:565-582.
43. O'Donnell B.F., Shenton M.E., McCarley R.W., et al. The auditory N2 component in schizophrenia: relationship to MRI temporal lobe gray matter and to other ERP abnormalities. Biol Psychiatry 1993, 34:26-40.
44. Pallanti S., Quercioli L., Pazzagli A. Basic symptoms and P300 abnormalities in young schizophrenic patients. Compr Psychiatry 1999, 14:101-106.
45. Pfefferbaum A., Ford J.M., White P.M., et al. P3 in schizophrenia is affected by stimulus modality, response requirements, medication status, and negative symptoms. Arch Gen Psychiatry 1989, 46:1035-1044.
46. Polich J. Clinical application of P300 event-related potential. Phys Med Rehabil Clin N Am 2004, 15:133-161.
47. Polich J., Squire L. P300 from amnesic patients with bilateral hippocampal lesions. Electroencephalogr Clin Neurophysiol 1993, 86:408-417.
48. Posner M.I., Petersen S.E. The attention system of the human brain. Annu Rev Neurosci 1990, 13:25-42.
49. Purdon S.E. Cognitive improvement in schizophrenia with novel antipsychotic medications. Schizophr Res 1999, 35(Supp):S51-S60.
50. Roth W.T., Pfefferbaum A., Kelly A.F., et al. Auditory event-related potentials in schizophrenia and depression. Psychiatry Res 1981, 4:199-212.
51. Salisbury D., Shenton M., Sherwood A., et al. First-episode schizophrenic psychosis differs from first-episode affective psychosis and controls in P300 amplitude over left temporal lobe. Arch Gen Psychiatry 1998, 55:173-180.
52. Schall U., Catts S., Chaturvedi S., et al. The effect of clozapine therapy on frontal lobe dysfunction in schizophrenia: neuropsychology and event-related potential measures. Int J Neuropsychopharmacol 1998, 1:19-29.
53. Seidman L.J., Yurgelun-Todd D., Kremen W.S., et al. Relationship of prefrontal and temporal lobe MRI measures to neuropsychological performance in chronic schizophrenia. Biol Psychiatry 1994, 35:235-246.
54. Semlitsch H.V., Anderer P., Schuster P., et al. A solution for reliable and valid reduction of ocular artifacts, applied to the P300 ERP. Psychophysiology 1986, 23:695-703.
55. Shelley A.M., Grochowski S., Lieberman J.A., et al. Premature disinhibition of P generation in schizophrenia. Biol Psychiatry 1996, 39:714-719.
56. Spitzer R.L., Williams J.B.W., Gibbon M., et al. The Structured Clinical Interview for DSM-III-R (SCID). I: history, rationale, and description. Arch Gen Psychiatry 1992, 49:624-629.
57. Stockmeier C.A., DiCarlo J.J., Zhang Y., et al. Characterization of typical and atypical antipsychotic drugs based on in vivo occupancy of serotonin2 and dopamine2 receptors. J Pharmacol Exp Ther 1993, 266:1374-1384.
58. Strandbrug R.J., Marsh J.T., Brown W.S., et al. Reduced attention-related negative potential in schizophrenia adults. Psychophysiology 1994, 31:272-281.
59. Strik W.K., Dierks T., Maurer K. Amplitudes of auditory P300 in remitted and residual schizophrenics: correlations with clinical features. Neuropsychobiology 1993, 27:54-60.
60. Sumiyoshi T., Stockmeier C.A., Overholser J.C., et al. Dopamine D4 receptors and effects of guanine nucleotides on [3H] raclopride binding in postmortem caudate of subjects with schizophrenia or major depression. Brain Res 1995, 681:109-116.
61. Turetsky B., Colbath E.A., Gur R.E. P300 subcomponent abnormalities in schizophrenia: II. Longitudinal stability and relationship to symptom change. Biol Psychiatry 1998, 43:31-39.
62. Umbricht D., Javitt D., Novak G., et al. Effects of clozapine on auditory event-related potentials in schizophrenia. Biol Psychiatry 1998, 44:716-725.
63. Umbricht D., Javitt D., Novak G., et al. Effects of risperidone on auditory event-related potentials in schizophrenia. Int J Neuropsychopharmacol 1999, 2:299-304.
64. Voruganti L.P., Awad A.G., Parker G., et al. Cognition, functioning and quality of life in schizophrenia treatment: results of a one-year randomized controlled trial of olanzapine and quetiapine. Schizophr Res 2007, 96:146-155.
65. Ward P.B., Catts S.V., Fox A.M., et al. Auditory selective attention and event-related potentials in schizophrenia. Br J Psychiatry 1991, 158:534-539.
66. Wolkin A., Sanfilipo M., Wolf A.P., et al. Negative symptoms and hypofrontality in chronic schizophrenia. Arch Gen Psychiatry 1992, 49:959-965.
67. Woodward N.D., Purdon S.E., Meltzer H.Y., et al. A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int J Neuropsychopharmacology 2005, 8:457-472.
68. Zhang Y., Lehmann M., Shobeiry A., et al. Effects of quetiapine on cognitive functions in schizophrenic patients: a preliminary single-trial ERP analysis. Pharmacopsychiatry 2009, 42:129-134.